Having established the potent affinities of members of our analog library and their PKC translocation kinetics, we next sought to evaluate our close-in analogs in an assay pertinent to the clinical use of bryostatin and its analogs as adjuvants to enhance targeted cancer immunotherapies. The gene discussed is PRRT2; the disease is cancer.